- Life sciences investment team boosted by Investment Directors appointment
- Dr Andy Round to support and grow portfolio of companies across UK
Venture capital investment specialists, Deepbridge Capital, today announces the appointment of Dr Andy Round as Senior Investment Director.
As an experienced life sciences investment specialist, most recently as Director and Head of Healthcare at Praetura Ventures and previously at both Maven Capital Partners and MSIF, Dr Round will be working within Deepbridge’s Life Sciences Investment Team which manages the Deepbridge Life Sciences EIS fund.
This recruitment forms part of Deepbridge’s wider restructuring programme, following the promotion of Ben Carter to Head of Life Sciences and the additions of Simon Thelwall-Jones, David Blake and Oliver Wheatley to Deepbridge’s Tech Investment Team; with Dr Savvas Neophytou as Chief Investment Officer.
With over £230m invested to date and over 75% of investment being outside of London, Deepbridge is one of the most active regional early-stage investors in the UK; reporting a record year of fundraising during the 2021/22 tax year, supporting investee companies within the Deepbridge Technology Growth EIS and Deepbridge Life Sciences EIS funds.
Ian Warwick, Managing Partner at Deepbridge, commented; “My colleagues and I have known Andy for many years, having co-invested with Andy on numerous occasions, so we are delighted that he has now joined Deepbridge; which is testament to the quality of the life sciences companies in our portfolio.
“Despite the uncertainty surrounding the global economy, the UK continues to produce great life sciences and tech innovations which require funding to grow and become the leading companies of tomorrow. This is why the Enterprise Investment Scheme is such a crucial and generous scheme, which is the envy of the world.”
Ben Carter, Investment Director, Head of Life Sciences, added; “Our objective within the Deepbridge Life Sciences Investment Team is to identify, select and proactively support the very best early-stage life sciences opportunities across the UK. Andy’s domain expertise and wealth of experience will be an invaluable addition to our team as we seek to grow the great medtech, pharma, biotech and digital healthcare companies of tomorrow.”